Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 37 Issue 6
. 
Turn off MathJax
Article Contents
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2019  >  37(6): 563-570

LIN Lili, HUANG Aiwen, LIN Meiqin, FANG Jie, SHEN Qinyong, SONG Hongtao. The efficacy and safety of S-1 monotherapy or combined with platinum chemotherapy in the treatment of patients with advanced NSCLC: a meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(6): 563-570. doi: 10.3969/j.issn.1006-0111.2019.06.018
Citation: LIN Lili, HUANG Aiwen, LIN Meiqin, FANG Jie, SHEN Qinyong, SONG Hongtao. The efficacy and safety of S-1 monotherapy or combined with platinum chemotherapy in the treatment of patients with advanced NSCLC: a meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(6): 563-570. doi: 10.3969/j.issn.1006-0111.2019.06.018
shu

The efficacy and safety of S-1 monotherapy or combined with platinum chemotherapy in the treatment of patients with advanced NSCLC: a meta-analysis

doi: 10.3969/j.issn.1006-0111.2019.06.018
  • 1.

    Department of Pharmacy, 900 Hospital of Joint Logistics Units, Fuzhou 350025, China;Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China

  • 2.

    Department of Pharmacy, 900 Hospital of Joint Logistics Units, Fuzhou 350025, China

  • Received Date: 2019-02-21
  • Rev Recd Date: 2019-05-14
  • Objective To investigate the efficacy and safety of S-1 monotherapy or combined with platinum chemotherapy in the treatment of patients with advanced NSCLC. Methods Systematic searches were performed for randomized controlled trials with the CNKI,PubMed,Web of Science and Cochrane Library.S-1 monotherapy or combined with platinum chemotherapy was the observation group.Paclitaxel,docetaxel and gemcitabine monotherapy or combined with platinum chemotherapy were the control group.The Cochrane systematic review method was used for literature quality evaluation and RevMan 5.3.5 software was used for statistical analysis. Results 3977 patients were enrolled in 25 studies.The effective rate and disease control rate in the observation group were similar to those in the control group with no statistical significance[ORR:OR=0.97,95% CI (0.83,1.13),P=0.66; DCR:OR=1.11,95% CI (0.92,1.32) P=0.27].In terms of safety,there were less adverse drug reactions in the observation group compared to the control group with statistical significance (P<0.05). Conclusion S-1 monotherapy or combined with platinum chemotherapy is recommended for patients with advanced NSCLC.
  • [1] CRONIN K A,LAKE A J,SCOTT S,et al.Annual report to the nation on the status of cancer,part I:National cancer statistics[J].Cancer,2018,124(13):2785-2800.
    [2] SAKURADA T,KAKIUCHI S,TAJIMA S,et al.Characteristics of and risk factors for interstitial lung disease induced by chemotherapy for lung cancer[J].Ann Pharmacother,2015,49(4):398-404.
    [3] 余佳文,王增,程斌.替吉奥联合化疗治疗中晚期非小细胞肺癌的疗效和安全性的Meta分析[J].中国药房,2014,25(20):1897-1900.
    [4] YOSHIOKA H,OKAMOTO I,MORITA S,et al.Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer:updated results of the West Japan Oncology Group LETS study[J].Ann Oncol,2013,24(5):1326-1331.
    [5] OKAMOTO I,YOSHIOKA H,MORITA S,et al.Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-na?ve patients with advanced non-small-cell lung cancer:results of a west Japan oncology group study[J].J Clin Oncol,2010,28(36):5240-5246.
    [6] 陈婵娟,陈昌南,林云笑,等.替吉奥与紫杉醇联合铂类治疗老年中晚期非小细胞肺癌的临床对比分析[J].赣南医学院学报,2015,35(1):73-75.
    [7] 龙燕.替吉奥或紫杉醇联合顺铂治疗中晚期非小细胞肺癌的疗效比较[J].广东医学院学报, 2016,34(6):632-634.
    [8] 王继贤.紫杉醇脂联合顺铂与替吉奥联合顺铂在晚期非小细胞肺癌患者中的应用效果对比[J].癌症进展,2016,14(3):272-273.
    [9] 徐继业.紫杉醇联合顺铂与替吉奥联合顺铂治疗中晚期肺癌的对比分析[J].实用癌症杂志, 2016,31(10):1631-1633.
    [10] 柳宝,陈公琰.替吉奥与多西他赛分别联合顺铂一线治疗晚期非小细胞肺癌的临床观察[J].中国肿瘤临床与康复,2013,20(7):734-736.
    [11] 潘永军,沈广洪,邹晓瑜,等.替吉奥二线治疗老年晚期非小细胞肺癌疗效分析[J].中国肿瘤外科杂志,2015,7(5):312-314.
    [12] NISHINO K,IMAMURA F,KUMAGAI T,et al.A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110)[J].Lung Cancer,2015,89(2):146-153.
    [13] KUBOTA K,SAKAI H,KATAKAMI N,et al.A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer:TCOG0701 CATS trial[J].Ann Oncol,2015,26(7):1401-1408.
    [14] 王雨.探讨替吉奥与多西他赛单药方案一线治疗高龄晚期非小细胞肺癌的疗效分析[J].中国医药指南,2016,14(27):83-83.
    [15] 郭依龙,周恒根,倪敬中.替吉奥或多西他赛联合铂类治疗老年中晚期非小细胞肺癌的疗效和安全性[J].实用医学杂志,2016,32(22):3782-3784.
    [16] NOKIHARA H,LU S,MOK T S K,et al.Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)[J].Ann ?癮楣獯瑬愬猲嬰?崷??瀸渨????氲椶渹?伭渲挷漰氶?监ぢひ?????ㄠ??水????贺文茜,等.替吉奥联合顺铂与吉西他滨联合顺铂治疗晚期非小细胞肺癌的疗效对比观察[J].中国老年保健医学,2012,10(4):101-103.
    [17] 刘萍.替吉奥维持治疗晚期非小细胞肺癌临床疗效观察[J].中国全科医学,2013,16(11):1038-1040.
    [18] 石彧,王志祥.替吉奥维持治疗晚期非小细胞肺癌的临床疗效观察[J].中国医药指南,2014,12(4):169-170.
    [19] 孔静,张一桥.替吉奥联合顺铂治疗晚期非小细胞肺癌的临床疗效[J].中国肿瘤临床与康复.2014,21(12):1455-1458.
    [20] 孙成晖,吴国强,严伟红,等.替吉奥和吉西他滨分别联合顺铂一线治疗EGFR野生型的晚期非小细胞肺癌的临床观察[J].中国医院药学杂志,2015,35(23):2129-2132.
    [21] 王碧荣,李卫东,邓旭斌,等.替吉奥维持治疗EGFR野生型晚期非小细胞肺癌临床观察[J].中国现代医生,2016,54(19):87-90.
    [22] 史磊,张国耀,马天江.替吉奥与吉西他滨分别联合顺铂一线治疗Ⅳ期非小细胞肺癌的临床观察[J].中国实用医药,2016,11(15):164-165.
    [23] 陈巧霞.吉西他滨与替吉奥在老年中晚期非小细胞肺癌治疗中的对比研究[J].医药论坛杂志,2017,38(5):134-136.
    [24] 施湘萍.替吉奥或吉西他滨联合顺铂一线治疗EGFR野生型晚期非小细胞肺癌40例临床评价[J].中国药业,2017,26(22):52-54.
    [25] 钱滨滨.替吉奥与吉西他滨分别联合顺铂治疗EGFR野生型肺癌研究[J].中国继续医学教育,2017,9(31):106-108.
    [26] 李景,周彩云,宋敏,等.探讨替吉奥胶囊单药治疗老年晚期非小细胞肺癌的临床效果[J].中国现代药物应用,2018,12(21):85-86.
    [27] 陈伟.替吉奥和吉西他滨分别联合顺铂治疗晚期非小细胞肺癌的临床观察[J].中国医药指南,2018,16(6):5-6.
    [28] YE T,PAN Y J,WANG R,et al.Analysis of the molecular and clinicopathologic features of surgically resected lung adenocarcinoma in patients under 40 years old[J].J Thorac Dis,2014,6(10):1396-1402.
    [29] SCHILLER J H,HARRINGTON D,BELANI C P,et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J].N Engl J Med,2002,346(2):92-98.
    [30] ICHINOSE Y,YOSHIMORI K,SAKAI H,et al.S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer:A multi-institutional phase II trial[J].Clin Cancer Res,2004,10(23):7860-7864.
    [31] DI MAIO M,PERRONE F,CHIODINI P,et al.Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer[J].J Clin Oncol,2007,25(11):1377-1382.
    [32] JAPANESE GASTRIC CANCER ASSOCIATION.Japanese gastric cancer treatment guidelines 2014(ver.4)[J].Gastric Cancer,2017,20(1):1-19.
    [33] SHIRASAKA T.Development history and concept of an oral anticancer agent S-1(TS-1):its clinical usefulness and future
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(3315) PDF downloads(864) Cited by()

Related
Proportional views

The efficacy and safety of S-1 monotherapy or combined with platinum chemotherapy in the treatment of patients with advanced NSCLC: a meta-analysis

doi: 10.3969/j.issn.1006-0111.2019.06.018
  • 1. Department of Pharmacy, 900 Hospital of Joint Logistics Units, Fuzhou 350025, China;Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China
  • 2. Department of Pharmacy, 900 Hospital of Joint Logistics Units, Fuzhou 350025, China
  • Received Date: 2019-02-21
  • Rev Recd Date: 2019-05-14

Abstract: Objective To investigate the efficacy and safety of S-1 monotherapy or combined with platinum chemotherapy in the treatment of patients with advanced NSCLC. Methods Systematic searches were performed for randomized controlled trials with the CNKI,PubMed,Web of Science and Cochrane Library.S-1 monotherapy or combined with platinum chemotherapy was the observation group.Paclitaxel,docetaxel and gemcitabine monotherapy or combined with platinum chemotherapy were the control group.The Cochrane systematic review method was used for literature quality evaluation and RevMan 5.3.5 software was used for statistical analysis. Results 3977 patients were enrolled in 25 studies.The effective rate and disease control rate in the observation group were similar to those in the control group with no statistical significance[ORR:OR=0.97,95% CI (0.83,1.13),P=0.66; DCR:OR=1.11,95% CI (0.92,1.32) P=0.27].In terms of safety,there were less adverse drug reactions in the observation group compared to the control group with statistical significance (P<0.05). Conclusion S-1 monotherapy or combined with platinum chemotherapy is recommended for patients with advanced NSCLC.

LIN Lili, HUANG Aiwen, LIN Meiqin, FANG Jie, SHEN Qinyong, SONG Hongtao. The efficacy and safety of S-1 monotherapy or combined with platinum chemotherapy in the treatment of patients with advanced NSCLC: a meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(6): 563-570. doi: 10.3969/j.issn.1006-0111.2019.06.018
Citation: LIN Lili, HUANG Aiwen, LIN Meiqin, FANG Jie, SHEN Qinyong, SONG Hongtao. The efficacy and safety of S-1 monotherapy or combined with platinum chemotherapy in the treatment of patients with advanced NSCLC: a meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(6): 563-570. doi: 10.3969/j.issn.1006-0111.2019.06.018
shu

    HTML

Reference (33)

Catalog

    版权所有：《药学实践与服务》编辑委员会

    Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

    Tel: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    Supported by: Beijing Renhe Information Technology Co., Ltd.  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return